need for hospitalization based on severe or critical symptoms based on cdc guidance. subject in long-term care facility. known hypersensitivity or contra-indication to tempol. subjects taking strong cyp inhibitors (e.g. fluoxetine, itraconazole, quinidine, clarithromycin). in the opinion of the investigator, any reason that would make the follow up of the subject impossible during the study treatment and follow up period. any reason the subject cannot comply with study and study procedures. subjects receiving any other investigational agent within 4 weeks of baseline/day 1. use of non-fda approved (eua or full approval)/off label treatments for covid-19. lactating females. history of any known chronic liver or kidney disease. subjects taking drugs with a narrow therapeutic index such as cyclosporine digoxin flecainide lithium phenytoin sirolimus theophylline, and warfarin.

need for hospitalization based on severe or critical symptoms based on cdc guidance. subject in long-term care facility. known hypersensitivity or contra-indication to tempol. subjects taking strong cyp inhibitors (e.g. fluoxetine, itraconazole, quinidine, clarithromycin). in the opinion of the investigator, any reason that would make the follow up of the subject impossible during the study treatment and follow up period. any reason the subject cannot comply with study and study procedures. subjects receiving any other investigational agent within 4 weeks of baseline/day 1. use of non-fda approved (eua or full approval)/off label treatments for covid-19. lactating females. history of any known chronic liver or kidney disease. subjects taking drugs with a narrow therapeutic index such as cyclosporine digoxin flecainide lithium phenytoin sirolimus theophylline, and warfarin.

- need for hospitalization based on severe or critical symptoms based on cdc guidance. - subject in long-term care facility. - known hypersensitivity or contra-indication to tempol. - in the opinion of the investigator, any reason that would make the follow up of the subject impossible during the study treatment and follow up period. any reason the subject cannot comply with study and study procedures. - subjects receiving any other investigational agent within 4 weeks od baseline/day 1. - lactating females. - evidence of any known chronic liver or kidney disease. - estimated glomerular filtration rate (egfr) <60 ml/min/1.73m2 within 14 days of baseline. - serum ast/alt/total bilirubin levels greater than 2 times upper limit of normal within 14 days of baseline. - prior covid-19 vaccination or prior recovery from documented covid-19 infection.

- need for hospitalization based on severe or critical symptoms based on cdc guidance. - subject in long-term care facility. - known hypersensitivity or contra-indication to tempol. - in the opinion of the investigator, any reason that would make the follow up of the subject impossible during the study treatment and follow up period. any reason the subject cannot comply with study and study procedures. - subjects receiving any other investigational agent within 4 weeks od baseline/day 1. - lactating females. - evidence of any known chronic liver or kidney disease. - estimated glomerular filtration rate (egfr) <60 ml/min/1.73m2 within 14 days of baseline. - serum ast/alt/total bilirubin levels greater than 2 times upper limit of normal within 14 days of baseline. - prior covid-19 vaccination or prior recovery from documented covid-19 infection.

- need for hospitalization based on severe or critical symptoms based on cdc guidance. - subject in long-term care facility. - subject without confirmation of sar-cov2 infection by laboratory test. - known hypersensitivity or contra-indication to tempol. - any reason making follow up of the subject impossible during the study period. - subjects receiving any other investigational agent within 4 weeks. - pregnant or lactating females. positive urine pregnancy test at baseline. - evidence of any known chronic liver or kidney disease.

- need for hospitalization based on severe or critical symptoms based on cdc guidance. - subject in long-term care facility. - subject without confirmation of sar-cov2 infection by laboratory test. - known hypersensitivity or contra-indication to tempol. - any reason making follow up of the subject impossible during the study period. - subjects receiving any other investigational agent within 4 weeks. - pregnant or lactating females. positive urine pregnancy test at baseline. - evidence of any known chronic liver or kidney disease.